AEZS:CA:TSX-Aeterna Zentaris Inc (CAD)

COMMON STOCK | Biotechnology | TSX

Last Closing Price

CAD 0.52

Change

-0.03 (-5.45)%

Market Cap

CAD 0.07B

Volume

0.13M

Avg Analyst Target

CAD 2.00 (+284.62%)

Avg User Target

CAD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Aeterna Zentaris Inc (AEZS) Stock Analysis:
Based on the Aeterna Zentaris Inc stock forecasts from 1 analysts, the average analyst target price for Aeterna Zentaris Inc is CAD 2.00 over the next 12 months. Aeterna Zentaris Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Aeterna Zentaris Inc is Slightly Bullish , which is based on 7 positive signals and 5 negative signals. At the last closing, Aeterna Zentaris Inc’s stock price was CAD 0.52. Aeterna Zentaris Inc’s stock price has changed by -0.09 % over the past week, -0.22 % over the past month and -5.45 % over the last year.

About

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, a peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by bindi ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-12-03 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
TRIL:CA Trillium Therapeutics Inc

N/A

CAD2.43B 1.80 N/A
BLU:CA BELLUS Health Inc

-0.33 (-4.66%)

CAD0.55B N/A N/A
LMNL:CA Liminal BioSciences Inc

N/A

CAD0.54B 1.28 N/A
APS:CA Aptose Biosciences Inc

-0.13 (-4.83%)

CAD0.24B N/A N/A
IMV:CA IMV Inc

-0.16 (-8.33%)

CAD0.16B -99,999.99 N/A
FRX:CA Fennec Pharmaceuticals Inc

+0.26 (+4.73%)

CAD0.16B 30.20 N/A
MDNA:CA Medicenna Therapeutics Corp

-0.17 (-7.69%)

CAD0.13B 5.40 N/A
ONC:CA Oncolytics Biotech Inc

-0.08 (-3.79%)

CAD0.12B N/A N/A
RVX:CA Resverlogix Corp

N/A

CAD0.11B 30.71 26.37
MBX:CA Microbix Biosystems Inc

N/A

CAD0.10B 31.70 111.10

ETFs Containing AEZS:CA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.70% 73% C 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.70% 73% C 21% F
Trailing 12 Months  
Capital Gain -5.45% 67% D+ 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.45% 67% D+ 16% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 5.83% 38% F 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.83% 38% F 42% F
Risk Return Profile  
Volatility (Standard Deviation) 73.90% 50% F 12% F
Risk Adjusted Return 7.88% 38% F 17% F
Market Capitalization 0.07B 35% F 26% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 13.60 57% F 51% F
Price/Book Ratio 0.87 100% A+ 81% B-
Price / Cash Flow Ratio -16.76 82% B- 88% B+
EV/EBITDA 2.14 100% A+ 91% A-
Management Effectiveness  
Return on Equity -17.30% 100% A+ 16% F
Return on Invested Capital -120.19% 29% F 2% F
Return on Assets -7.10% 94% A 12% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 6.31 29% F 18% F
Short Percent 0.41% 56% F 72% C-
Beta 2.01 19% F 12% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.